Believer, Endocrinologist, Writer, Co-Founder. Program Director of Allen Diabetes Center @HoagHealth. I love talking digital health, diabetes, and sports.
Excited to be on the Advisory Committee for the inaugural #CRC2026. Take the stage and present your work on type 1 diabetes! Abstract submissions are open until April 15, 2026: https://t.co/pft8scuVHT
Join me in Philadelphia!
#DiabetesResearch#Type1Diabetes#T1DResearch
🩸Bridging the #diabetes care gap means training specialists equipped for today’s complex therapeutic landscape.
In this video, Dr. Ahn (@AhnCall@hoaghealth) shares how @ACDiabetology is doing so through dedicated #diabetology fellowships: https://t.co/Z0j6FsaikH
#MedTwitter
If it pans out, cheaper obesity meds are a win for patients, esp since Medicare has been so hard to get coverage! But what about the Medicare Prescription Drug, Improvement, Modernization Act of 2003, which excludes AOM’s from Part D coverage? @BevTchangMD@MichaelAlbertMD
Medicare telehealth coverage is only secure through Sept. 30, 2025—and Congress will need to act again this year to extend it.
Urge your members of Congress to protect access to care and make Medicare telehealth permanent.
👉 https://t.co/MITlS6yjVs
@Kidfears99@VertexPharma Ahh… i get it. Totally fair. For this one, I personally think it’s a big and important step in the progress toward a cure, but definitely not a reasonable option itself for 99% of people with T1D.
Seeing the CEO of Hims/Hers, the literal pill mill for GLP ones, accusing Novo of not factoring in what was clinically best for patients is unhinged and ironic.
We are disappointed to see Novo Nordisk management misleading the public.
In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.
We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first.
We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.
We reported the first long term double blind study of Semaglutide in type 1 diabetes. Semaglutide is effective in reducing weight, insulin dose and HbA1c in type 1 diabetes.
TING (70-140 mg/dL) and TIR (70-180 mg/dL) are greater indicators for diabetic complications at #ADA2025 by @TBattelino
Time to retire HbA1c and use CGM metrics for follow up.
JJ Spaun lost 40 pounds from 2017 to 2021, dropping to 584 in the world golf ranking.
Doctors told him he had Type 2 diabetes, but he kept losing weight, only to find out two years later he had Type 1 diabetes.
Now, he’s a top 25 player and U.S. Open champion. What a comeback.
In a historic and unprecedented move, all of the institutions at the @NIH have signed on to and sent a letter, the Bethesda Declaration, to the new director, Dr. Jay Bhattacharya, about the chaos at the NIH. This is a big deal, as it ultimately impacts all of us. It impacts the research that gets done or not done. It impacts what we know or what we will never know. Let’s see what the response will be, as the director is scheduled to testify before Congress tomorrow about the NIH’s budget.
In other news, speaking of unprecedented, Bhattacharya‘s boss just removed all 17 members of the CDC’s vaccine advisers, saying the group is “plagued with conflicts of interest.”
It’s a chaotic, unprecedented time. Do not let anyone tell you otherwise. Yes the noise is loud, but we must continue to pay attention to what matters and stay informed and engaged! #abovethenoise
This is absolutely stunning. I covered ACIP from 1994-2011. Initially most members had Pharma disclosures, but later they moved toward inclusion of multiple members without such ties. And it was always totally transparent. How will removing expertise restore confidence? #vaccines
Really excited to partake in this debate as I go toe to toe with @DianaMIsaacs on the pros/cons of OTC CGM’s like #stelo and #lingo. I’m taking the con perspective, so it should be fun playing the villain! 😅 #ADASciSessions
Don't miss an exciting #ADASciSessions debate where experts will assess the benefits and drawbacks of OTC CGMs.
Learn more in ADA Meeting News: https://t.co/lnz4pCivTc